可溶性AGE受体与1型糖尿病肾病及其进展
基于芬兰FinnDiane研究3647例1型糖尿病患者的基线血清sRAGE,分析其与糖尿病肾病及进展的关系。基线sRAGE在糖尿病肾病患者中最高,与大量白蛋白尿进展至终末期肾病相关,但校正eGFR后关联消失;孟德尔随机化分析不支持sRAGE与进展至ESRD存在因果关系。
要点
- 基线sRAGE在糖尿病肾病患者中最高,但与大量白蛋白尿进展至ESRD的关联在校正eGFR后消失。
- sRAGE在传统危险因素之上不增加对ESRD进展的预测价值。
- 孟德尔随机化分析不支持sRAGE与大量白蛋白尿进展至ESRD存在因果关系。
核心结论
- sRAGE与大量白蛋白尿进展至ESRD相关,但在传统危险因素之上不增加预测价值。
- 孟德尔随机化分析不支持sRAGE与大量白蛋白尿进展至ESRD存在因果关系。
研究设计与样本
- 基于芬兰全国多中心FinnDiane研究,测量3647例1型糖尿病患者的基线血清sRAGE。
- 采用回归、竞争风险和ROC曲线分析评估sRAGE与糖尿病肾病及其进展的关联。
- 使用非同义SNP rs2070600(G82S)进行孟德尔随机化分析以检验因果关系。
主要发现
- 基线sRAGE浓度在糖尿病肾病患者中最高,高于正常白蛋白排泄率或微量白蛋白尿患者。
- 竞争风险分析显示基线sRAGE与大量白蛋白尿进展至ESRD相关,但模型中纳入eGFR后关联消失。
- SNP rs2070600与sRAGE浓度及大量白蛋白尿进展至ESRD强烈相关,但孟德尔随机化分析不支持sRAGE对进展至ESRD的因果作用。
临床怎么用
- sRAGE可作为糖尿病肾病的生物标志物,但不建议在传统危险因素之外单独用于预测ESRD进展。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Activation of the receptor for AGE (RAGE) has been shown to be associated with diabetic nephropathy. The soluble isoform of RAGE (sRAGE) is considered to function as a decoy receptor for RAGE ligands and thereby protects against diabetic complications. A possible association between sRAGE and diabetic nephropathy is still, however, controversial and a more comprehensive analysis of sRAGE with respect to diabetic nephropathy in type 1 diabetes is therefore warranted. METHODS: sRAGE was measured in baseline serum samples from 3647 participants with type 1 diabetes from the nationwide multicentre Finnish Diabetic Nephropathy (FinnDiane) Study. Associations between sRAGE and diabetic nephropathy, as well as sRAGE and diabetic nephropathy progression, were evaluated by regression, competing risks and receiver operating characteristic curve analyses. The non-synonymous SNP rs2070600 (G82S) was used to test causality in the Mendelian randomisation analysis. RESULTS: Baseline sRAGE concentrations were highest in participants with diabetic nephropathy, compared with participants with a normal AER or those with microalbuminuria. Baseline sRAGE was associated with progression from macroalbuminuria to end-stage renal disease (ESRD) in the competing risks analyses, but this association disappeared when eGFR was entered into the model. The SNP rs2070600 was strongly associated with sRAGE concentrations and with progression from macroalbuminuria to ESRD. However, Mendelian randomisation analysis did not support a causal role for sRAGE in progression to ESRD. CONCLUSIONS/INTERPRETATION: sRAGE is associated with progression from macroalbuminuria to ESRD, but does not add predictive value on top of conventional risk factors. Although sRAGE is a biomarker of diabetic nephropathy, in light of the Mendelian randomisation analysis it does not seem to be causally related to progression from macroalbuminuria to ESRD.
引用
- Wadén JM, Dahlström EH, Elonen N, et al. Soluble receptor for AGE in diabetic nephropathy and its progression in Finnish individuals with type 1 diabetes. Diabetologia. 2019. PMID: 31127314. doi:10.1007/s00125-019-4883-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。